Premium
Implantation of everolimus‐eluting bioresorbable scaffolds in a diabetic all‐comers population—the future is now?
Author(s) -
Sharma Ajay K.,
Levy Michael S.
Publication year - 2015
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26306
Subject(s) - medicine , everolimus , bioresorbable scaffold , population , surgery , percutaneous coronary intervention , myocardial infarction , environmental health
Key Points This article describes a single‐center experience of Everolimus‐eluting bioresorbable scaffolds as an alternative to drug eluting stents in diabetic patients with various presentations of coronary artery disease. The results suggest the possibility of a paradigm shift for treatment in this population as ultimately no metallic remains are left to act as a nidus for inflammation. The study suggests the benefits as well as technical limitations of the current bioresorbable scaffold (BRS) technology, such as increased strut thickness, decreased deliverability, and increase in major cardiovascular events compared to current drug eluting stent (DES) technology.